Improvement of Glucose Tolerance in NIDDM by Clofibrate Randomized Double-Blind Study
- Masashi Kobayashi, MD,
- Yukio Shigeta, MD,
- Yukimasa Hirata, MD,
- Yasue Omori, MD,
- Nobuo Sakamoto, MD,
- Seiki Nambu, MD and
- Shigeaki Baba, MD
- Department of Medicine, Shiga University of Medical Science Ohtsu Diabetes Center, Tokyo Women's Medical College Tokyo Department of Medicine, Nagoya University School of Medicine Nagoya Division of Atheroscleroses and Metabolism, National Cardiovascular Center Osaka Second Department of Medicine, Kobe University School of Medicine Kobe, Japan
- Address correspondence and reprint requests to Masashi Kobayashi, MD, Third Department Medicine, Shiga University of Medical Science, Ohtsu, Shiga 520–21, Japan.
Abstract
A randomized double-blind study was performed to examine the effect of clofibrate on glucose tolerance in subjects with non-insulin-dependent diabetes mellitus (NIDDM). Clofibrate (1.5 g/day) or placebo was administered to 70 patients and an oral glucose tolerance test (OGTT) was performed before and 12 wk after treatment. Blood glucose levels were significantly improved in clofibrate-treated groups at all time points during OGTT, whereas there was no change in insulin levels. Improvement of fasting glucose levels required 8 wk of clofibrate treatment. Insulin binding to erythrocytes demonstrated no significant change in the clofibrate-treated subjects.A randomized double-blind study was performed to examine the effect of clofibrate on glucose tolerance in subjects with non-insulin-dependent diabetes mellitus (NIDDM). Clofibrate (1.5 g/day) or placebo was administered to 70 patients and an oral glucose tolerance test (OGTT) was performed before and 12 wk after treatment. Blood glucose levels were significantly improved in clofibrate-treated groups at all time points during OGTT, whereas there was no change in insulin levels. Improvement of fasting glucose levels required 8 wk of clofibrate treatment. Insulin binding to erythrocytes demonstrated no significant change in the clofibrate-treated subjects. These results suggest that clofibrate improves glucose tolerance in NIDDM subjects without a change in insulin receptors and that clofibrate increases insulin sensitivity through an unknown postreceptor mechanism.
- Copyright © 1988 by the American Diabetes Association
